CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
India Budget 2025 Highlights Manufacturing Push but Falls Short of Market Expectations 
Gold Prices Stabilize in Asian Trade After Sharp Weekly Losses Amid Fed Uncertainty 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Russia Stocks End Flat as MOEX Closes Unchanged Amid Mixed Global Signals 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Oil Prices Slide Nearly 3% as U.S.-Iran Talks Ease Geopolitical Tensions 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Philippines Manufacturing PMI Hits Nine-Month High Despite Weak Confidence Outlook 
U.S.–Venezuela Relations Show Signs of Thaw as Top Envoy Visits Caracas 
BOJ Policymakers Warn Weak Yen Could Fuel Inflation Risks and Delay Rate Action 
IMF Forecasts Global Inflation Decline as Growth Remains Resilient 
Dollar Holds Firm as Markets Weigh Warsh-Led Fed and Yen Weakness Ahead of Japan Election 
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
China Manufacturing PMI Slips Into Contraction in January as Weak Demand Pressures Economy 
Samsung Biologics is expanding its CMO or contract manufacturing organization business, and as part of its plans, it is constructing its very first overseas production plant in the United States.
On Monday, June 13, Samsung Biologics’ chief executive officer, John Rim, shared that they are considering several locations for the facility. He said that the strongest candidates for their CMO site are Texas, North Carolina, California, and Washington.
According to The Korea Herald, Samsung Biologics is looking into these places more because many of the major bio companies’ facilities are also operating in the mentioned US states. At this time, the company has not yet made any decision and carefully reviewing the areas to choose the best option.
“We are certainly expanding and the Plant 4 will begin partial operation in October, adding a 60,000-liter production capacity,” the Samsung Biologics’ CEO told the media during the press meeting for the 2022 BIO International Convention in San Diego, California. “By the second quarter of next year, it will have a 180,000-liter production capacity.”
While planning to build its first manufacturing plant abroad, Samsung Biologics has already set up its fourth factory in Songdo, Incheon, in South Korea. Once this facility starts operating at its full capacity, it is expected to boost production.
All in all, the four plants should produce 620,000 liters of products for around 30% of the global demand. It was said that Samsung Biologics’ Plant 4 currently has the biggest CMO production capacity in the world, with 256,000 liters of products in a single facility.
Rim revealed that they are also aiming to build the fifth and sixth factories in South Korea, and this is why they are buying more land in Incheon. The purchases were originally expected to be completed by the end of May, but the authorities could not sign the contract because the government officials who are in charge, which are the mayor and commissioner of the Incheon Free Economic Zone, have changed due to the local elections that was held earlier this month.
Finally, the Samsung Biologics chief said that they still plan to go ahead with the construction of Plant 5 and 6. However, they will not be monitoring the supply and demand trends to see if there is still a need to build more factories.
